search
Back to results

A Study to Evaluate Efficacy and Safety of Light Dose in Subjects With PWB Treated With Hemoporfin + PDT

Primary Purpose

Port-wine Birthmark, Port-Wine Stain, Nevus Flammeus

Status
Not yet recruiting
Phase
Phase 2
Locations
Study Type
Interventional
Intervention
Hemopfin+PDT
Vehicle+PDT
Sponsored by
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Port-wine Birthmark focused on measuring Hemoporfin, Port-wine Birthmark, Port-Wine Stain, Nevus Flammeus, Photodynamic therapy

Eligibility Criteria

18 Years - 65 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

- 1. Subject must be 18 to 65 years of age inclusive, at the time of signing the informed consent.

2. Subject is Fitzpatrick skin type I-VI. 3. A male subject must agree to use contraception during the Treatment Period and for at least 6 months after the last dose of study treatment and refrain from donating sperm during this period.

4. A female subject is eligible to participate if she is not pregnant, not breastfeeding, and at least one of the following conditions applies:

  1. Not a woman of childbearing potential (WOCBP) . OR
  2. A WOCBP who agrees to follow the contraceptive guidance during the Treatment Period and for at least 30 days after the last dose of study treatment.

    5. The subject has a clinical diagnosis of PWS located on the face and/or neck. The PWS target lesion on the face and/or neck must have a severity score of Grade ≥3 on the PWS IGA scale at screening and baseline.

    6. The longest diameter of the treatment area is ≥3 cm, and the short diameter is ≥2 cm.

    7. Subject is capable of giving signed informed consent , which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol.

    8. Subject, in the Investigator's opinion, is in good general health and free of any disease state or physical condition that may impair the evaluation of PWS or expose the subject to an unacceptable risk by study participation.

    Exclusion Criteria:

    • 1. Subject is pregnant, lactating, or is planning to become pregnant during the study.

      2. Subject has plaque/nodular changes and severe hypertrophy within the target PWS area.

      3. Subject has Sturge-Weber syndrome or PWS involving ophthalmic nerves. 4. Subject has any skin pathology or condition that, in the Investigator's opinion, could interfere with the evaluation of the study drug or requires use of interfering topical, systemic, or surgical therapy.

      5. Subject has evidence of scarring within the target PWS area and/or subject has a history of hypertrophic scarring or keloidal scarring.

      6. Subject has PWS lesion located in the eyelid, orbital region, auricle, nasal alar, nasolabial fold, lip region, lips, or oral cavity.

      7. Subject is immunosuppressed related to medication use and/or disease . 8. Subject has a hereditary or acquired coagulation disorder or is taking anti coagulants (eg, high and middle dose aspirin) regularly within three weeks of Day 1.

      9. Subject has clinically significant ECG abnormalities at Screening 10. Subject has clinically significant laboratory abnormalities as assessed by the Investigator at Screening.

      11. Subject has impaired renal (serum creatinine and blood urea nitrogen [BUN] ≥1.5 × upper limit of normal [ULN]) or hepatic (elevated alanine aminotransferase [ALT] or aspartate transaminase [AST] ≥3 × ULN with concurrent elevation in total bilirubin ≥2 × ULN function).

      12. Subject has received any therapy on the treatment region that, in the Investigator's opinion, may affect the target PWS area.

      13. Subject has a history of cutaneous photosensitization, porphyria, or photodermatosis.

      14. Subject has the need or has plans to be exposed to artificial tanning devices or excessive sunlight during the study.

      15. Subject has received any therapy, including PDT, to treat PWS in the treatment area within 6 months prior to the initiation of treatment.

      16. Subject is currently enrolled in an investigational drug or device study, including clinical studies in dermatology.

      17. Subject has used an investigational drug or investigational device treatment within 30 days prior to Day 1.

      18. Subject has a history of sensitivity to any of the ingredients in the study drug, including porphyrins, mannitol, and drugs with similar chemical structures.

      19. Subject is known or in the opinion of the Investigator likely to be noncompliant with the requirements of the study protocol (eg, due to alcoholism, drug dependency, mental incapacity).

      20. Subject has a history of either significant neurological events (such as major stroke) or a mental condition rendering him/her unable to understand the nature, scope, and possible consequences of the study.

      21. Subject has an unstable cardiac disease or has any medical condition that in the opinion of the Investigator may worsen from receipt of study treatment or subject participation.

      22. Subject is currently taking other photosensitizing medications such as tetracyclines, sulfonamides, phenothiazine, sulfonylurea hypoglycemic agents, thiazide diuretics, quinolones, vitamin A acid, and griseofulvin that may potentially increase the photosensitive reaction in the skin.

      23. Subjects currently taking compounds that can eliminate reactive oxygen species or scavenge free radicals such as β-carotene, ethanol, and formate, which may also reduce the activity of Hemoporfin.

Sites / Locations

    Arms of the Study

    Arm 1

    Arm 2

    Arm 3

    Arm 4

    Arm 5

    Arm 6

    Arm Type

    Experimental

    Experimental

    Experimental

    Placebo Comparator

    Placebo Comparator

    Placebo Comparator

    Arm Label

    Hemoporfin+A J/cm2 PDT

    Hemoporfin+B J/cm2PDT

    Hemoporfin+C J/cm2 PDT

    Placebo+A J/cm2 PDT

    Placebo+B J/cm2PDT

    Placebo+C J/cm2 PDT

    Arm Description

    Participants will receive Hemoporfin 5 mg/kg of body weight via intravenous (IV) infusion and fixed laser irradiation for certain time.

    Participants will receive Hemoporfin 5 mg/kg of body weight via intravenous (IV) infusion and fixed laser irradiation for certain time.

    Participants will receive Hemoporfin 5 mg/kg of body weight via intravenous (IV) infusion and fixed laser irradiation for certain time.

    Participants will receive Vehicle (Saline) via intravenous (IV) infusion and fixed laser irradiation for certain time.

    Participants will receive Vehicle (Saline) via intravenous (IV) infusion and fixed laser irradiation for certain time.

    Participants will receive Vehicle (Saline) via intravenous (IV) infusion and fixed laser irradiation for certain time.

    Outcomes

    Primary Outcome Measures

    Stage One:Incidence of any local and systemic adverse events.
    To compare the efficacy of multiple light doses (fluence) of Hemoporfin PDT To investigate the safety of multiple light doses (fluence) of Hemoporfin/vehicle PDT in subjects with Port-wine birthmark (PWB)
    Stage Two: Port Wine Birthmark-Investigator Global Assessment (PWB-IGA) scale score reduction.
    To compare the efficacy of multiple light doses (fluence) of Hemoporfin PDT with vehicle PDT in subjects with PWB of face and/or neck.

    Secondary Outcome Measures

    Stage One:Change from Baseline in overall PWB-IGA severity score and other scales.
    To further evaluate the efficacy of multiple light doses (fluence) of Hemoporfin/vehicle PDT in subjects with PWB.
    Stage Two: Change from Baseline in overall PWB-IGA severity score and other scales.
    To further evaluate the efficacy of multiple light doses (fluence) of Hemoporfin/vehicle PDT in subjects with PWB.
    Stage Two: Incidence of any local and systemic adverse events.
    To investigate the safety of multiple light doses (fluence) of Hemoporfin/vehicle PDT in subjects with Port-wine birthmark (PWB)

    Full Information

    First Posted
    November 15, 2021
    Last Updated
    September 7, 2023
    Sponsor
    Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.
    search

    1. Study Identification

    Unique Protocol Identification Number
    NCT05171894
    Brief Title
    A Study to Evaluate Efficacy and Safety of Light Dose in Subjects With PWB Treated With Hemoporfin + PDT
    Official Title
    A Multi-Center, Randomized, Double-Blind, Vehicle-Controlled, Sequential Group Comparison Study to Evaluate the Safety and Efficacy of Light Dose (Fluence) in Subjects With Port-wine Birthmark of the Face and/or Neck Treated With Hemoporfin + Green Light Photodynamic Therapy
    Study Type
    Interventional

    2. Study Status

    Record Verification Date
    June 2023
    Overall Recruitment Status
    Not yet recruiting
    Study Start Date
    August 31, 2023 (Anticipated)
    Primary Completion Date
    January 2026 (Anticipated)
    Study Completion Date
    April 2026 (Anticipated)

    3. Sponsor/Collaborators

    Responsible Party, by Official Title
    Sponsor
    Name of the Sponsor
    Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.

    4. Oversight

    Studies a U.S. FDA-regulated Drug Product
    No
    Studies a U.S. FDA-regulated Device Product
    No

    5. Study Description

    Brief Summary
    This is a multi-center, randomized, double-blind, vehicle-controlled, and sequential group Phase 2 study. Eligible subjects aged 18 to 65 years old with PWB of face and/or neck area (except subjects for Stage One) will receive Hemoporfin PDT or vehicle PDT in 8-week cycles at fixed drug dose (5 mg/kg) and different light fluence.
    Detailed Description
    This is a multi-center, randomized, double-blind, vehicle-controlled, and sequential group Phase 2 study. Eligible subjects aged 18 to 65 years old with PWB of face and/or neck area (except subjects for Stage One) will receive Hemoporfin PDT or vehicle PDT in cycles at fixed drug dose (5 mg/kg) and different light fluences. This study will be conducted in two sequential stages, each contains the same schedule, which includes Screening Period, Treatment Period apart; subsequent treatment is based on efficacy evaluation, and End of Study.

    6. Conditions and Keywords

    Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
    Port-wine Birthmark, Port-Wine Stain, Nevus Flammeus
    Keywords
    Hemoporfin, Port-wine Birthmark, Port-Wine Stain, Nevus Flammeus, Photodynamic therapy

    7. Study Design

    Primary Purpose
    Treatment
    Study Phase
    Phase 2
    Interventional Study Model
    Parallel Assignment
    Masking
    ParticipantCare ProviderInvestigatorOutcomes Assessor
    Allocation
    Randomized
    Enrollment
    84 (Anticipated)

    8. Arms, Groups, and Interventions

    Arm Title
    Hemoporfin+A J/cm2 PDT
    Arm Type
    Experimental
    Arm Description
    Participants will receive Hemoporfin 5 mg/kg of body weight via intravenous (IV) infusion and fixed laser irradiation for certain time.
    Arm Title
    Hemoporfin+B J/cm2PDT
    Arm Type
    Experimental
    Arm Description
    Participants will receive Hemoporfin 5 mg/kg of body weight via intravenous (IV) infusion and fixed laser irradiation for certain time.
    Arm Title
    Hemoporfin+C J/cm2 PDT
    Arm Type
    Experimental
    Arm Description
    Participants will receive Hemoporfin 5 mg/kg of body weight via intravenous (IV) infusion and fixed laser irradiation for certain time.
    Arm Title
    Placebo+A J/cm2 PDT
    Arm Type
    Placebo Comparator
    Arm Description
    Participants will receive Vehicle (Saline) via intravenous (IV) infusion and fixed laser irradiation for certain time.
    Arm Title
    Placebo+B J/cm2PDT
    Arm Type
    Placebo Comparator
    Arm Description
    Participants will receive Vehicle (Saline) via intravenous (IV) infusion and fixed laser irradiation for certain time.
    Arm Title
    Placebo+C J/cm2 PDT
    Arm Type
    Placebo Comparator
    Arm Description
    Participants will receive Vehicle (Saline) via intravenous (IV) infusion and fixed laser irradiation for certain time.
    Intervention Type
    Drug
    Intervention Name(s)
    Hemopfin+PDT
    Other Intervention Name(s)
    Fumeida with green light photodynamic therapy
    Intervention Description
    All qualified subjects randomized to Hemoporfin PDT treatment to receive up to 3 cycles of treatment.
    Intervention Type
    Drug
    Intervention Name(s)
    Vehicle+PDT
    Other Intervention Name(s)
    saline with green light photodynamic therapy
    Intervention Description
    All qualified subjects randomized to vehicle PDT treatment to receive up to 3 cycles of treatment.
    Primary Outcome Measure Information:
    Title
    Stage One:Incidence of any local and systemic adverse events.
    Description
    To compare the efficacy of multiple light doses (fluence) of Hemoporfin PDT To investigate the safety of multiple light doses (fluence) of Hemoporfin/vehicle PDT in subjects with Port-wine birthmark (PWB)
    Time Frame
    From baseline until end of study, up to approximately 44 weeks
    Title
    Stage Two: Port Wine Birthmark-Investigator Global Assessment (PWB-IGA) scale score reduction.
    Description
    To compare the efficacy of multiple light doses (fluence) of Hemoporfin PDT with vehicle PDT in subjects with PWB of face and/or neck.
    Time Frame
    From baseline until end of study, up to approximately 44 weeks
    Secondary Outcome Measure Information:
    Title
    Stage One:Change from Baseline in overall PWB-IGA severity score and other scales.
    Description
    To further evaluate the efficacy of multiple light doses (fluence) of Hemoporfin/vehicle PDT in subjects with PWB.
    Time Frame
    From baseline until end of study, up to approximately 44 weeks
    Title
    Stage Two: Change from Baseline in overall PWB-IGA severity score and other scales.
    Description
    To further evaluate the efficacy of multiple light doses (fluence) of Hemoporfin/vehicle PDT in subjects with PWB.
    Time Frame
    From baseline until end of study, up to approximately 44 weeks
    Title
    Stage Two: Incidence of any local and systemic adverse events.
    Description
    To investigate the safety of multiple light doses (fluence) of Hemoporfin/vehicle PDT in subjects with Port-wine birthmark (PWB)
    Time Frame
    From baseline until end of study, up to approximately 44 weeks
    Other Pre-specified Outcome Measures:
    Title
    Stage One:Maximum observed plasma concentration (Cmax) of Hemoporfin
    Description
    To check what time will it take to reach the maximum contraction of Hemoporfin
    Time Frame
    On the first day of the Cycle 1 (each cycle is 56 days)
    Title
    Stage One:Area under the concentration-time curve (AUC 0-∞) from time 0 to infinity of Hemoporfin
    Description
    To check the drug profile for absorption, distribution, metabolism and excretion for Hemoporfin
    Time Frame
    On the first day of the Cycle 1 (each cycle is 56 days)
    Title
    Stage One:Terminal elimination half-life (t1/2) of Hemoporfin
    Description
    To check how much time Hemoporfin will take to eliminate half of it's concentration from participants.
    Time Frame
    On the first day of the Cycle 1 (each cycle is 56 days)
    Title
    Stage One:Time to Cmax (Tmax) of Hemoporfin
    Description
    To check what will be the maximum concentration participants will obtained of Hemoporfin
    Time Frame
    On the first day of the Cycle 1 (each cycle is 56 days)

    10. Eligibility

    Sex
    All
    Minimum Age & Unit of Time
    18 Years
    Maximum Age & Unit of Time
    65 Years
    Accepts Healthy Volunteers
    No
    Eligibility Criteria
    Inclusion Criteria: Subject must be 18 to 65 years of age inclusive, at the time of signing the informed consent. Subject is Fitzpatrick skin type I-VI. A male subject must agree to use contraception during the Treatment Period and for at least 6 months after the last dose of study treatment and refrain from donating sperm during this period. A female subject is eligible to participate if she is not pregnant, not breastfeeding, and at least one of the following conditions applies: Not a woman of childbearing potential (WOCBP) . OR A WOCBP who agrees to follow the contraceptive guidance during the Treatment Period and for at least 30 days after the last dose of study treatment. The subject has a clinical diagnosis of PWB located on the face and/or neck. The longest diameter of the treatment area is ≥3 cm, and the short diameter is ≥2 cm. Subject is capable of giving signed informed consent, which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol. Subject, in the Investigator's opinion, is in good general health and free of any disease state or physical condition that may impair the evaluation of PWB or expose the subject to an unacceptable risk by study participation. Exclusion Criteria: Subject is pregnant, lactating, or is planning to become pregnant during the study. Subject has plaque/nodular changes and severe hypertrophy within the target PWB area. Subject has Sturge-Weber syndrome or PWB involving ophthalmic nerves. Subject has any skin pathology or condition that, in the Investigator's opinion, could interfere with the evaluation of the study drug or requires use of interfering topical, systemic, or surgical therapy. Subject is immunosuppressed related to medication use and/or disease. Subject has clinically significant ECG abnormalities at Screening Subject has clinically significant laboratory abnormalities as assessed by the Investigator at Screening. Subject has received any therapy on the treatment region that, in the Investigator's opinion, may affect the target PWB area. Subject is currently enrolled in an investigational drug or device study, including clinical studies in dermatology. Subject has used an investigational drug or investigational device treatment within 30 days prior to C1D1. Subject is known or in the opinion of the Investigator likely to be noncompliant with the requirements of the study protocol (eg, due to alcoholism, drug dependency, mental incapacity). Subject has a history of either significant neurological events (such as major stroke) or a mental condition rendering him/her unable to understand the nature, scope, and possible consequences of the study. Subject has an unstable cardiac disease or has any medical condition that in the opinion of the Investigator may worsen from receipt of study treatment or subject participation.
    Central Contact Person:
    First Name & Middle Initial & Last Name or Official Title & Degree
    Xuejing Cheng
    Phone
    00-86-021-58953355
    Email
    xjcheng@fd-zj.com

    12. IPD Sharing Statement

    Citations:
    PubMed Identifier
    25047192
    Citation
    Qin ZP, Li KL, Ren L, Liu XJ. Photodynamic therapy of port wine stains-a report of 238 cases. Photodiagnosis Photodyn Ther. 2007 Mar;4(1):53-9. doi: 10.1016/j.pdpdt.2007.01.001. Epub 2007 Feb 12.
    Results Reference
    background

    Learn more about this trial

    A Study to Evaluate Efficacy and Safety of Light Dose in Subjects With PWB Treated With Hemoporfin + PDT

    We'll reach out to this number within 24 hrs